An immunomodulatory photosensitizer-mediated photodynamic therapy synergizes with PD-L1 blockade against metastatic triple-negative breast cancer
The clinical potency of anti-programmed death-ligand 1 (PD-L1) therapy in metastatic triple-negative breast cancer (TNBC) is modest primarily because of the intrinsic low immunogenicity and an immunosuppressive tumor microenvironment (TME). Photodynamic therapy (PDT), an inducer of immunogenic cell...
Saved in:
Main Authors: | Yuetong Liu, Liming Wang, Feiyan Kong, Tianjun Liu, Hong Liu |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2025-07-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2025.1651165/full |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
An Albumin‐Photosensitizer Supramolecular Assembly with Type I ROS‐Induced Multifaceted Tumor Cell Deaths for Photodynamic Immunotherapy
by: Jingtian Zhang, et al.
Published: (2025-03-01) -
Polymer-assisted PD-L1 degradation and targeted photodynamic therapy synergize to suppress immunodeficient tumors
by: Changyong Guo, et al.
Published: (2025-07-01) -
PD-L1 expression predicts the efficacy of PD-1 blockade plus chemotherapy versus chemotherapy alone in treatment-naïve advanced or metastatic gastric cancer: a pooled analysis of reconstructed individual patient-level data from two randomized trials
by: Wei Zhou, et al.
Published: (2025-07-01) -
PD-L1-targeted polymer-peptide-immune nanomedicine synergizes radiotherapy for durable tumor control
by: Jincheng Du, et al.
Published: (2025-09-01) -
Programmed death ligand 1 (PD-L1) expression in gastric cancer: literature review
by: T. N. Sotnikova, et al.
Published: (2023-07-01)